<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - QUININE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>QUININE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Nocturnal leg cramps</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200&#8211;300 mg once daily, to be taken at bedtime.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Non-falciparum malaria</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg/kg every 8 hours (max. per dose 700 mg), infused over 4 hours, given if patient is unable to take oral therapy. Changed to oral chloroquine as soon as the patient&#8217;s condition permits.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Falciparum malaria</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                600 mg every 8 hours for 5&#8211;7 days, to be given together with or followed by either doxycycline or clindamycin.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Loading dose 20 mg/kg (max. per dose 1.4 g), infused over 4 hours, the loading dose of 20 mg/kg should not be used if the patient has received quinine or mefloquine during the previous 12 hours, then maintenance 10 mg/kg every 8 hours (max. per dose 700 mg) until patient can swallow tablets to complete the 7-day course, to be given 8 hours after the start of the loading dose and infused over 4 hours, the quinine should be given together with or followed by either doxycycline or clindamycin.</li>
              <li class="dose child"><strong>For children </strong><br/>
                10 mg/kg every 8 hours (max. per dose 600 mg) for 7 days, to be given with or followed by either clindamycin or, in children over 12 years, doxycycline.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Falciparum malaria (in intensive care unit)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Loading dose 7 mg/kg, infused over 30 minutes, followed immediately by 10 mg/kg, infused over 4 hours, then maintenance 10 mg/kg every 8 hours (max. per dose 700 mg) until patient can swallow tablets to complete the 7-day course, to be given 8 hours after the start of the loading dose and infused over 4 hours, the quinine should be given together with or followed by either doxycycline or clindamycin.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>When using quinine for malaria, doses are valid for quinine hydrochloride, dihydrochloride, and sulfate; they are <b>not valid</b> for quinine bisulfate which contains a correspondingly smaller amount of quinine.</p><p>Quinine (anhydrous base) 100&#8239;mg = quinine bisulfate 169&#8239;mg; quinine dihydrochloride 122&#8239;mg; quinine hydrochloride 122&#8239;mg; and quinine sulfate 121&#8239;mg. Quinine bisulfate 300&#8239;mg tablets are available but provide less quinine than 300&#8239;mg of the dihydrochloride, hydrochloride, or sulfate.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>High doses are teratogenic in <i>first trimester</i>, but in malaria benefit of treatment outweighs risk.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For treatment of malaria in severe impairment, reduce parenteral maintenance dose to 5&#8211;7&#8239;mg/kg of quinine salt.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For treatment of malaria in severe impairment, reduce parenteral maintenance dose to 5&#8211;7&#8239;mg/kg of quinine salt.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Haemoglobinuria</li>
            <li>myasthenia gravis</li>
            <li>optic neuritis</li>
            <li>tinnitus</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Agitation, tinnitus, abdominal pain, acute renal failure, angioedema, blood disorders, cardiovascular effects, cinchonism, confusion, diarrhoea, dyspnoea, flushed skin, headache, hearing impairment, hot skin, hypersensitivity reactions, hypoglycaemia (especially after parenteral administration), intravascular coagulation, muscle weakness, nausea, photosensitivity, rashes, temporary blindness, thrombocytopenia, vertigo, visual disturbances, vomiting,
              </p>
        
        
        
            <section class="overdosageInformation">
              <p>Quinine is very toxic in overdosage; life-threatening features include arrhythmias (which can have a very rapid onset) and convulsions (which can be intractable).</p><p>For details on the management of poisoning, see <xref format="dita" href="#PHP78558" type="bookmark" namespace="/treatment-summaries/emergency-treatment-of-poisoning">Emergency treatment of poisoning</xref>.</p>
            </section>
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, dilute to a concentration of 2&#8239;mg/mL (max. 30&#8239;mg/mL in fluid restriction) with Glucose 5% <i>or</i> Sodium Chloride 0.9% and give over 4 hours.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i>, give continuously in Glucose 5% or Sodium Chloride 0.9%. To be given over 4 hours.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Atrial fibrillation (monitor ECG during parenteral treatment)
          </li>
          <li>
            cardiac disease (monitor ECG during parenteral treatment)
          </li>
          <li>
            conduction defects (monitor ECG during parenteral treatment)
          </li>
          <li>
              <strong>:</strong>
            elderly (monitor ECG during parenteral treatment) in adults
          </li>
          <li>
            G6PD deficiency
          </li>
          <li>
            heart block (monitor ECG during parenteral treatment)
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Monitor blood glucose and electrolyte concentration during parenteral treatment.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">In adults</h3>
              <p>Patients taking quinine for nocturnal leg cramps should be monitored closely during the early stages for adverse effects as well as for benefit.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Injection not licensed.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Intravenous injection of quinine is so hazardous that it has been superseded by infusion.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of QUININE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            solution for infusion,
            oral solution,
            capsule,

            <div id="PHP76440"><a href="../medicinalForm/PHP76440.html" data-target="#PHP76440" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
